Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 19 of the 66 sources its claims cite were checked for support.
Abstract
Emerging data demonstrate that the activity of immune cells can be modulated by microbial molecules. Here, we show that the short-chain fatty acids (SCFAs) pentanoate and butyrate enhance the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells through metabolic and epigenetic reprograming. We show that in vitro treatment of CTLs and CAR T cells with pentanoate and butyrate increases the function of mTOR as a central cellular metabolic sensor, and inhibits class I histone deacetylase activity. This reprogramming results in elevated production of effector molecules such as CD25, IFN-γ and TNF-α, and significantly enhances the anti-tumor activity of antigen-specific CTLs and ROR1-targeting CAR T cells in syngeneic murine melanoma and pancreatic cancer models. Our data shed light onto microbial molecules that may be used for enhancing cellular anti-tumor immunity. Collectively, we identify pentanoate and butyrate as two SCFAs with therapeutic utility in the context of cellular cancer immunotherapy.
Overview
CoChat Summary
TL;DR
The paper shows that the microbial short-chain fatty acids pentanoate and butyrate enhance the anti-tumor activity of cytotoxic T lymphocytes and chimeric antigen receptor T cells through metabolic and epigenetic reprogramming. It identifies these SCFAs as potential tools for improving adoptive cancer immunotherapy.
Key findings
- Among 16 human commensals tested, the two *Megasphaera massiliensis* strains DSM 26228 and NCIMB 42787 were the only strong producers of both pentanoate and butyrate; *M. elsdenii* also produced pentanoate but at lower levels, while *F. prausnitzii* and *A. hadrus* produced high butyrate.
- Pentanoate and butyrate increased IFN-γ+TNF-α+ CTLs and TNF-α secretion, inhibited class I HDAC enzymes but not class II HDACs, increased mTOR and S6 phosphorylation and ECAR, and acted independently of GPR41/GPR43.
- Ex vivo pretreatment with pentanoate or butyrate improved anti-tumor immunity in B16OVA melanoma, with decreased tumor volume and weight and higher transferred CD8+ T cells producing IFN-γ and TNF-α in draining lymph nodes; pentanoate-treated OT-I CTLs abrogated PancOVA tumor growth and persisted after remission.
- Pentanoate and butyrate enhanced murine ROR1-CAR T cells (CD25, TNF-α, IFN-γ; reduced tumor volume and weight) and human ROR1-CAR T cells (CD25, IL-2, IFN-γ, TNF-α, proliferation, cytolysis); however, in vivo pentanoate administration did not enhance anti-tumor immunity or anti-PD-1 therapy.
Methods
- Murine and human CD8+ T cells, CTLs, and CAR T cells were cultured with SCFAs (e.g., 0.75 mM butyrate and 2.5 mM pentanoate for murine CAR T cells; 1 mM butyrate and 4 mM pentanoate for human CD8+ T cells) or HDAC inhibitors; bacterial supernatants from 16 commensals were analyzed by GC-MS, and HDAC activity, ECAR, ELISA, and flow cytometry were used.
- In vivo, B16OVA, PancOVA, or Panc02/ROR1 tumors were injected s.c. into CD45.2+ mice, followed by adoptive transfer of CD45.1+ OT-I CTLs or ROR1-CAR T cells on day 5; tumor volume/weight and T cell responses were analyzed, with persistence studied in Rag1-deficient mice co-transferred with Tregs and Foxp3−CD4+ T cells.
- Statistical analysis used two-tailed unpaired Student’s t-test and, for multiple groups, a linear-mixed effects model with Tukey correction; p < 0.05 was considered significant.
Limitations
- The paper states that involvement of other microbial metabolites in supernatant effects cannot be excluded, that clinical implementation of SCFA administration requires further investigation of optimal route, dosing, and schedule to balance effector versus regulatory immune subsets, and that the complex crosstalk between SCFA-mediated epigenetic changes and metabolic effects should be investigated further.
- Evident from the text: most mechanistic and efficacy data are from murine models and in vitro human CAR T cells, with no human clinical trial data; systemic in vivo pentanoate did not enhance anti-tumor immunity or anti-PD-1 therapy, so the therapeutic benefit shown is mainly from ex vivo pretreatment.
- Evident from the text: several experiments used small samples, such as n = 3 mice or three human donors, which limits generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 28 Not checked · 81 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The intestinal microbiota has been shown to directly impact on the efficacy of specific cancer immune therapies1–3.”
§ Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer > Introduction
What the sources say
- Supportedcites [1] Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015). source
The Results passage on combining fecal transfer with checkpoint blockade (p. null, 'To test whether manipulation of the microbial community could be effective as a therapy...') states outright that 'commensal microbial composition can influence spontaneous antitumor immunity, as well as a response to immunotherapy with αPD-L1 mAb,' and that αPD-L1 therapy alone was significantly more efficacious in JAX than TAC mice. The Abstract and Discussion likewise tie intestinal microbiota (Bifidobacterium) to the activity of anti–PD-1/PD-L1 immunotherapy, exactly the topic the citing sentence invokes as background. The evidence is murine and the mechanism is host-T-cell-mediated rather than a direct effect on tumor cells, but the attributed content — microbiota impacting the efficacy of a specific cancer immunotherapy — is what our copy reports. (LLM, conf=0.85)
- Partly supportedcites [2] Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018). sourceExperimental — accuracy not yet measured
Our copy supports the substance: in metastatic melanoma patients a significant association was found between commensal microbial composition and clinical response to anti–PD-1 (Abstract), and fecal reconstitution of germ-free mice with responder vs. nonresponder stool made anti–PD-L1 'markedly efficacious in mice colonized with R microbiota yet completely ineffective in NR-derived mice... demonstrating a profound impact of the commensal microbiota on immunotherapy efficacy in vivo' (Results, Fig. 3F passage). However, the direct/causal demonstration is in the mouse reconstitution model, while in patients the paper reports an association and hedges the mechanism: 'Our results suggest that the commensal microbiome may have a mechanistic impact on antitumor immunity in human cancer patients' (Abstract), and its Discussion stresses that comparisons across the other microbiome–checkpoint studies (refs. 7,14) 'should be addressed with caution'. So the unqualified 'has been shown to directly impact the efficacy of specific cancer immune therapies' states as established fact, and generalizes beyond PD-1/PD-L1 blockade in melanoma, what this source shows causally only in germ-free mice and as association in humans. (LLM, conf=0.72)
- Not checked yetcites [3] Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Our broad screening approach revealed that among the commensal strains tested, only a few bacterial species exhibited a strong pan-HDAC inhibitory capacity21.”
§ Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer > Results > Butyrate and pentanoate inhibit HDAC class I enzymes and increase mTOR activity in CD8+ T cells
What the sources say
- Partly supportedcites [21] Yuille, S., Reichardt, N., Panda, S., Dunbar, H. & Mulder, I. E. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS ONE 13, e0201073 (2018). sourceExperimental — accuracy not yet measured
The screening part is supported: our copy (Results, 'Gut commensals inhibit total HDAC activity in whole HT-29 cells and on HT-29 cell lysate'; Fig 1A legend) reports that CFS of 79 commensal strains were screened for total HDAC inhibition and only three strains — M. massiliensis MRx0029, R. intestinalis MRx0071, B. massiliensis MRx1342 — had the strongest effect, with the Discussion adding that no propionate-producing strain showed strong inhibition. However, the 'pan-HDAC' descriptor is not what this source supports: the isoform-level work ('Potent total HDAC inhibitors investigated target class I HDACs'; Fig 4 legend) states only class I HDAC2 and HDAC3 were inhibited, with no significant impact on class II HDACs and no HDAC1 inhibition, and the paper frames these commensals as selective class I inhibitors. So the claim's magnitude/'few species' element is in it, but attributing pan-HDAC capacity to these strains overstates the source. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“It is known that the glycolytic metabolic pathway promotes IFN-γ expression and T cell effector function20,24–27.”
§ Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer > Results > Butyrate and pentanoate inhibit HDAC class I enzymes and increase mTOR activity in CD8+ T cells
What the sources say
- Supportedcites [20] Luu, M. et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nat. Commun. 10, 760 (2019). source
The Discussion of our copy states outright that "Normally, upon activation of T cells, the metabolic reprogramming towards glycolysis supports their inflammatory phenotype and production of cytokines such as IFN-γ or IL-17A" (Discussion, p. ~10), which is exactly the background point the citing sentence attributes ("It is known that..."). The Results ("Pentanoate induces IL-10 expression in effector T cells") reinforce the link between glucose/glycolytic metabolism and effector cytokine output, and the paper's refs 42–43 (Shi et al. 2011; Chang et al. 2013) are the works it credits for this established point — consistent with a general background citation rather than a claim of original discovery here. (LLM, conf=0.86)
- Supportedcites [24] Chang, C. H. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239–1251 (2013). source
The SUMMARY (p. 1) states that aerobic glycolysis is specifically required for effector function in T cells and that blocking glycolysis markedly compromises IFNg production. The section 'Aerobic Glycolysis Is Required for Optimal IFNg Cytokine Production in T Cells' (p. 4) reports that galactose-cultured (non-glycolyzing) T cells had a severe defect in IFNg (and IL-2) production, and the DISCUSSION (p. 10) concludes that only aerobic glycolysis can facilitate full effector status. The mechanism is translational (p. 4-5, 'Aerobic Glycolysis Controls the Preferential Translation of IFNg mRNA'), so 'expression' here refers to IFNg protein rather than mRNA, which does not contradict the claim. (LLM, conf=0.93)
- Supportedcites [25] Peng, M. et al. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 354, 481–484 (2016). source
The Abstract of Peng et al. (2016) states that aerobic glycolysis 'is a metabolic hallmark of activated T cells, and has been implicated in augmenting effector T cell responses including expression of the pro-inflammatory cytokine interferon (IFN)-γ', and concludes that 'aerobic glycolysis promotes effector T cell differentiation' via LDHA maintaining acetyl-CoA for histone acetylation and Ifng transcription. A body passage (Introduction/Results, p. cited as [2]) likewise opens 'Glycolysis promotes expression of effector molecules including the type 1 cytokine IFN-γ', and the LDHA-deficient Th1 cells showed diminished IFN-γ expression, matching the paraphrased claim. (LLM, conf=0.92)
- Supportedcites [26] Qiu, J. et al. Acetate promotes T cell effector function during glucose restriction. Cell Rep. 27, 2063–2074 (2019). e2065. source
The INTRODUCTION of our copy states directly that "Glycolysis promotes IFN-γ expression both through epigenetic and post-transcriptional mechanisms," and that glycolysis inhibition raises PD-1 and drives exhaustion, i.e. impairs effector function. The same section frames glucose/glycolysis as required for T cell activation, clonal expansion and effector molecule expression (IFN-γ), so the broad background statement in the citing sentence matches how this paper treats the topic. The citing sentence adds no population or magnitude beyond what the source asserts. (LLM, conf=0.90)
- Supportedcites [27] Cham, C. M. & Gajewski, T. F. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J. Immunol. 174, 4670–4677 (2005). source
The Discussion/abstract passage (p. 4670) states that glucose deprivation strongly inhibited IFN-γ gene expression while IL-2 was little affected, and that optimal induction of IFN-γ transcription is a glucose-dependent process. The Introduction (p. 4670) adds that effector CD8+ T cells up-regulate eight glycolytic enzyme genes, display higher glucose uptake and glycolytic rate, and that 'glucose is mandatory for a subset of signaling pathways and gene expression events' with implications for T cell effector function. This is a fair paraphrase of the source, though the source's data are in vitro CD8+ effector T cells rather than T cells generally. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We have recently demonstrated that the SCFA pentanoate (valerate) is also a bacterial metabolite present in the gut of conventional but not of germ-free (GF) mice20.”
§ Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer > Introduction
What the sources say
- Supportedcites [20] Luu, M. et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nat. Commun. 10, 760 (2019). source
The Results section, “Pentanoate suppresses IL-17A production,” reports pentanoate in the gut lumen of wild-type mice but not germ-free mice and describes it as a likely product of bacterial fermentation. The Discussion explicitly says it is present in conventional but not germ-free mice. (LLM, conf=0.94)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that in vitro treatment of CTLs and CAR T cells with pentanoate and butyrate increases the function of mTOR as a central cellular metabolic sensor”
§ Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
71 more claims
Create a free account to see all 122 claims and to verify the 47 references still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 27
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Selective metabolites produced by distinct intestinal bacteria modulate cancer immunosurveillance in extraintestinal tumors.”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pending further confirmation, these results suggest that SCFAs display context-dependent immune effects that range from the differentiation of Treg cells to the enhancement of effector T cell functions.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“the production of gut microbial metabolites (polyamines 58,65-67 , short-chain fatty acids [68][69][70][71] , indoles [72][73][74][75] , vitamins [76][77][78][79] , bile acids 80,81 ) that impact the cancer-immunity dialog.”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [71]
In the citing paper
“SCFAs can directly promote the antitumor cytotoxicity of CD8 T cells in vivo and in vitro [6, 88] (Fig. 4B).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer > Results > Pentanoate and butyrate treatment enhances the anti-tumor reactivity of antigen-specific CD8+ T cells
“On day 10 after adoptive transfer of CTLs, we detected a higher percentage as well as absolute number of pentanoate- and butyrate-pretreated CD8+ T cells, expressing more TNF-α and IFN-γ in comparison to non-treated OT-I CTLs in draining LNs (Fig. 3d–g).”
§ Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer > Results > Pentanoate and butyrate treatment enhances the anti-tumor reactivity of antigen-specific CD8+ T cells
“The percentage (e) and total cell number (f) of transferred CD8+CD45.1+ OT-I CTLs in the tumor-draining LNs at day 14 after tumor inoculation are shown.”
Citations
Cites
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
Cited by
Short-chain fatty acids: Linking diet, the microbiome and immunity
Mann, E. R., Lam, Y. K., & Uhlig, H. H. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01014-8 · Cited by 1,595
“The immunomodulatory properties of SCFAs, particularly butyrate, might apply to tumour-specific cytotoxic T lymphocytes and CAR T cells 96 .”
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis
Wang, J., Zhu, N., Su, X., Gao, Y., & Yang, R. (2023) · Cells · doi:10.3390/cells12050793 · Cited by 588
Cullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Metadata
- Authors
- Luu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., Picard, F., Muhammad, K., Ohl, K., Romero, R., Fischer, F., Bauer, C. A., Huber, M., Gress, T. M., Lauth, M., Danhof, S., Bopp, T., Nerreter, T., Mulder, I. E., Steinhoff, U., Hudecek, M., & Visekruna, A.
- Affiliations
- Philipps University of Marburg (DE)
- Universitätsklinikum Würzburg (DE)
- Johannes Gutenberg University Mainz (DE)
- United Arab Emirates University (AE)
- RWTH Aachen University (DE)
- Corresponding author
- Hudecek, Michael
- Visekruna, Alexander
- ORCID
- Luu, Maik
- Riester, Zeno
- Busetti, Alessandro
- Klein, Matthias
- Raifer, Hartmann
- Picard, Felix
- Muhammad, Khalid
- Ohl, Kim
- Romero, Rossana
- Bauer, Christian A.
- Huber, Magdalena
- Gress, Thomas M.
- Lauth, Matthias
- Danhof, Sophia
- Bopp, Tobias
- Nerreter, Thomas
- Mulder, Imke E.
- Steinhoff, Ulrich
- Hudecek, Michael
- Visekruna, Alexander
- Venue
- Nature Communications
- Published
- 2021-07-01
- Volume
- 12
- Issue
- 1
- Pages
- 4077-4077
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8249424
- OpenAlex
- W3175895832
- Cited by
- 771
- References
- 47
- Citations by year
- 2026: 193 · 2025: 217 · 2024: 157 · 2023: 118 · 2022: 79 · 2021: 7
- FWCI
- 33.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
- RWTH Publications (RWTH Aachen) (submittedVersion, other-oa)
- RWTH Publications (RWTH Aachen)
- Funders
- Deutsche Forschungsgemeinschaft (DFG-KFO325)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- short-chain fatty acids, butyrate, CD8+ T cells, cytotoxic T lymphocytes, chimeric antigen receptor T cells, ROR1, adoptive immunotherapy, cancer immunotherapy, mTOR signaling, histone deacetylase, epigenetic reprogramming, cellular metabolism, melanoma, pancreatic cancer, antitumor immunity
- MeSH terms
- Animals, Butyrates, Fatty Acids, Volatile, Female, Immunologic Factors, Immunotherapy, Interferon-gamma, Melanoma, Mice, Inbred C57BL, Neoplasms, Peptide Fragments, T-Lymphocytes, Cytotoxic, Tumor Necrosis Factor-alpha, Cytokines, Immunotherapy, Adoptive, CD8-Positive T-Lymphocytes, Receptors, G-Protein-Coupled, Cell Line, Tumor, Megasphaera, Mice, Interleukin-2 Receptor alpha Subunit, Receptor Tyrosine Kinase-like Orphan Receptors, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. https://app.cochat.ai/papers/10.1038/s41467-021-24331-1
- The paper
- Luu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., Picard, F., Muhammad, K., Ohl, K., Romero, R., Fischer, F., Bauer, C. A., Huber, M., Gress, T. M., Lauth, M., . . . Visekruna, A. (2021). Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nature Communications. https://doi.org/10.1038/s41467-021-24331-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.